Welcome to our dedicated page for Theratechnologies SEC filings (Ticker: THTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biopharma filing can feel like reading another language鈥攅specially when Theratechnologies鈥� disclosures cover peptide science, FDA updates, and concentrated drug revenue. If you have ever searched for 鈥淭heratechnologies SEC filings explained simply鈥� or wondered how a single 10-K weaves together clinical trial data, patent strategy, and revenue from EGRIFTA and Trogarzo, this page is built for you.
Stock Titan鈥檚 AI pinpoints the exact section you need鈥攚hether it is the R&D footnote in a Theratechnologies annual report 10-K simplified, the revenue breakout in a Theratechnologies quarterly earnings report 10-Q filing, or a sudden 8-K material events explained after an FDA notice. Our platform delivers real-time alerts on Theratechnologies Form 4 insider transactions, tracks executive stock transactions Form 4, and surfaces trends before they hit the headlines. Curious about dilution risk? The AI highlights equity financings. Need quick context on pipeline spend? You will find it summarized in plain English.
With comprehensive coverage of every form鈥�10-K, 10-Q, 8-K, S-3, DEF 14A proxy statement executive compensation, plus Theratechnologies insider trading Form 4 transactions鈥攜ou can move from document drop to informed decision in minutes. Investors routinely use this analysis to: 1) compare quarter-over-quarter R&D burn, 2) monitor Theratechnologies earnings report filing analysis for product-launch progress, and 3) follow Theratechnologies Form 4 insider transactions real-time when clinical milestones approach. Stop digging through PDFs; understanding Theratechnologies SEC documents with AI is faster, clearer, and always up to date.
Schedule 13G/A (Amendment 3) filed by Morgan Stanley discloses that its ownership in Theratechnologies Inc. (THTX) has fallen below the 5 % reporting threshold. As of 30 Jun 2025, the bank beneficially owns 858,614 common shares (CUSIP 88338H704), equal to 1.9 % of the outstanding class.
- Sole voting power: 0 shares
- Shared voting power: 852,939 shares
- Sole dispositive power: 0 shares
- Shared dispositive power: 858,614 shares
The filer is classified as a parent holding company/control person (HC, CO). Morgan Stanley certifies the shares are held in the ordinary course of business and not with intent to influence control. The amendment serves to notify investors that Morgan Stanley is no longer a 5 %+ beneficial owner of THTX.
FAQ
What is the current stock price of Theratechnologies (THTX)?
What is the market cap of Theratechnologies (THTX)?
